APA (7th ed.) Citation

Li, Y., Chu, Y., Shi, G., Wang, X., Ye, W., Shan, C., . . . Wu, H. (2022). A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer. Acta Pharmaceutica Sinica B, 12(11), 4165. https://doi.org/10.1016/j.apsb.2022.05.003

Chicago Style (17th ed.) Citation

Li, Yan, et al. "A Novel Inhibitor of ARfl and ARv7 Induces Protein Degradation to Overcome Enzalutamide Resistance in Advanced Prostate Cancer." Acta Pharmaceutica Sinica B 12, no. 11 (2022): 4165. https://doi.org/10.1016/j.apsb.2022.05.003.

MLA (9th ed.) Citation

Li, Yan, et al. "A Novel Inhibitor of ARfl and ARv7 Induces Protein Degradation to Overcome Enzalutamide Resistance in Advanced Prostate Cancer." Acta Pharmaceutica Sinica B, vol. 12, no. 11, 2022, p. 4165, https://doi.org/10.1016/j.apsb.2022.05.003.